Jump to Main Content
- Surnar, Bapurao; Kolishetti, Nagesh; Basu, Uttara; Ahmad, Anis; Goka, Erik; Marples, Brian; Kolb, David; Lippman, Marc E.; Dhar, Shanta
- Biochemistry 2018 v.57 no.46 pp. 6500-6513
- DNA; DNA damage; adverse effects; antineoplastic activity; aspirin; cisplatin; drug therapy; in vitro studies; models; nausea; nephrotoxicity; neurotoxicity; patients; urinary bladder neoplasms
- ... Cisplatin is a major chemotherapeutic that continues to have a significant impact in the treatment of more than 50% of all cancers. Since its Food and Drug Administration approval in 1978 for the treatment of advanced ovarian and bladder cancer, this chemotherapeutic has made significant strides and its application has been extended to a large variety of other cancers. However, the vast majority o ...
- Ambaye, Nigus; Chen, Chih-Hong; Khanna, Swati; Li, Yi-Jia; Chen, Yuan
- Biochemistry 2018 v.57 no.11 pp. 1807-1813
- antineoplastic activity; clinical trials; hypoxia; hypoxia-inducible factor 1; mutation; nuclear magnetic resonance spectroscopy; protein content; proteinases; sumoylation
- ... Streptonigrin (CAS no. 3930-19-6) is a natural product shown to have antitumor activities in clinical trials conducted in the 1960s–1970s. However, its use in clinical studies eventually faded, and the molecular mechanisms of streptonigrin antitumor effects remain poorly defined. Despite its lack of current clinical use, efforts on its total synthesis have continued. Here, we show that streptonigr ...
- PubMed Central: